NGR-hTNF: Preliminary Phase II data

Preliminary data from 17 evaluable patients in the single-arm, open-label, Italian Phase II NGR012 trial showed that IV NGR-hTNF plus doxorubicin led to a disease control rate of 70%. Based on the res...